Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience
황의진, 설종구, 이효진, 임재성,
소속 상세정보
황의진 ( Hwang Eu-Gene )
충남대학교 의과대학 비뇨기과학교실
설종구 ( Sul Chong-Koo )
충남대학교 의과대학 비뇨기과학교실
이효진 ( Lee Hyo-Jin )
충남대학교 의과대학 내과학교실
임재성 ( Lim Jae-Sung )
충남대학교 의과대학 비뇨기과학교실
KMID : 0358320100510070450
Abstract
Purpose: We assessed the efficacy and safety of the tyrosine kinase inhibitor sunitinib in Korean patients with metastatic renal cell carcinoma (mRCC).
Materials and Methods: Between September 2007 and December 2009, all twenty-one patients who had mRCC with a clear-cell component were retrospectively reviewed. Sunitinib was administered orally at a dose of 50 mg daily until disease progression or intolerance to treatment occurred. The primary end point of this study was the objective tumor response assessed by Response Evaluation Criteria in Solid Tumors (RECIST), and the secondary end points were progression-free survival (PFS) and overall survival (OS) rates as well as assessment of adverse effects.
Results: After a median of 17.4 months (range, 5.7-33.1 months) of treatment, 11 patients (52.4%) had an objective response with a complete response in 1 patient (4.8%), and a partial response in 10 patients (47.6%) as the best tumor response. The median PFS was 13.4 months (95% confidence interval [CI], range, 12.3-14.5 months), and the median OS was 28.1 months (95% CI, 21.8-34.4 months). All patients experienced adverse events of some sort, but the studied treatment protocol was well tolerated and most patients experienced reversible grade 1 or 2 toxicities.
Conclusions: Sunitinib was efficacious in the treatment of metastatic clear-cell RCC, and was well tolerated in Korean patients. Although sunitinib treatment-related adverse events such as hand-foot syndrome and facial/generalized edema were observed with a higher incidence than in Western trials, they were mainly mild to moderate, and readily managed.
키워드
Neoplasm metastasis;Renal cell carcinoma;Sunitinib
원문 및 링크아웃 정보
등재저널 정보